Anaplastic Astrocytoma - Pipeline Review, H2 2017

Published: May, 2017 | Pages: 150 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2017, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape.

Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Unknown stages are 4, 8, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 2 molecules, respectively.

Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Anaplastic Astrocytoma - Overview 8
Anaplastic Astrocytoma - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 16
Anaplastic Astrocytoma - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Anaplastic Astrocytoma - Companies Involved in Therapeutics Development 26
Advantagene Inc 26
Alfa Wassermann SpA 26
Amgen Inc 27
AngioChem Inc 27
Astellas Pharma Inc 28
Bayer AG 28
Boehringer Ingelheim GmbH 29
Burzynski Research Institute Inc 29
Cavion LLC 30
Celldex Therapeutics Inc 30
Merrimack Pharmaceuticals Inc 31
Millennium Pharmaceuticals Inc 31
Novartis AG 32
Orbus Therapeutics Inc 32
Pfizer Inc 33
Tocagen Inc 33
Tragara Pharmaceuticals Inc 34
TVAX Biomedical Inc 34
ZIOPHARM Oncology Inc 35
Anaplastic Astrocytoma - Drug Profiles 36
(A-10 + AS-21) - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
AdRTSIL-12 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
afatinib dimaleate - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
alisertib - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
BAY-1436032 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
bendamustine hydrochloride - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
CDX-1401 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Cellular Immunotherapy for Gliomas - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Cellular Immunotherapy for Oncology - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
eflornithine hydrochloride - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
flucytosine + TBio-01 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
flucytosine ER + vocimagene amiretrorepvec - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
G-207 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
GliAtak - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
irinotecan hydrochloride - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
irinotecan hydrochloride + TBio-02 - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
M-032 - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
mibefradil dihydrochloride - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
nilotinib - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
p28 - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
paclitaxel trevatide - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
palbociclib - Drug Profile 124
Product Description 124
Mechanism Of Action 124
R&D Progress 124
procarbazine hydrochloride - Drug Profile 137
Product Description 137
Mechanism Of Action 137
R&D Progress 137
TBX.OncV NSC - Drug Profile 138
Product Description 138
Mechanism Of Action 138
R&D Progress 138
TG-02 - Drug Profile 139
Product Description 139
Mechanism Of Action 139
R&D Progress 139
TOT-302 - Drug Profile 142
Product Description 142
Mechanism Of Action 142
R&D Progress 142
TVI-Brain-1 - Drug Profile 143
Product Description 143
Mechanism Of Action 143
R&D Progress 143
Anaplastic Astrocytoma - Dormant Projects 145
Anaplastic Astrocytoma - Discontinued Products 146
Anaplastic Astrocytoma - Product Development Milestones 147
Featured News & Press Releases 147
Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer 147
Dec 07, 2015: Burzynski Research Institute Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1 147
Jun 18, 2015: Burzynski Research Institute Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma 148
Appendix 149
Methodology 149
Coverage 149
Secondary Research 149
Primary Research 149
Expert Panel Validation 149
Contact Us 149
Disclaimer 150

List of Tables

Number of Products under Development for Anaplastic Astrocytoma, H2 2017 9
Number of Products under Development by Companies, H2 2017 11
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Universities/Institutes, H2 2017 13
Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15
Products under Development by Universities/Institutes, H2 2017 16
Number of Products by Stage and Target, H2 2017 18
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 19
Number of Products by Stage and Mechanism of Action, H2 2017 21
Number of Products by Stage and Route of Administration, H2 2017 23
Number of Products by Stage and Molecule Type, H2 2017 25
Anaplastic Astrocytoma - Pipeline by Advantagene Inc, H2 2017 26
Anaplastic Astrocytoma - Pipeline by Alfa Wassermann SpA, H2 2017 26
Anaplastic Astrocytoma - Pipeline by Amgen Inc, H2 2017 27
Anaplastic Astrocytoma - Pipeline by AngioChem Inc, H2 2017 27
Anaplastic Astrocytoma - Pipeline by Astellas Pharma Inc, H2 2017 28
Anaplastic Astrocytoma - Pipeline by Bayer AG, H2 2017 28
Anaplastic Astrocytoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017 29
Anaplastic Astrocytoma - Pipeline by Burzynski Research Institute Inc, H2 2017 29
Anaplastic Astrocytoma - Pipeline by Cavion LLC, H2 2017 30
Anaplastic Astrocytoma - Pipeline by Celldex Therapeutics Inc, H2 2017 30
Anaplastic Astrocytoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 31
Anaplastic Astrocytoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 32
Anaplastic Astrocytoma - Pipeline by Novartis AG, H2 2017 32
Anaplastic Astrocytoma - Pipeline by Orbus Therapeutics Inc, H2 2017 33
Anaplastic Astrocytoma - Pipeline by Pfizer Inc, H2 2017 33
Anaplastic Astrocytoma - Pipeline by Tocagen Inc, H2 2017 33
Anaplastic Astrocytoma - Pipeline by Tragara Pharmaceuticals Inc, H2 2017 34
Anaplastic Astrocytoma - Pipeline by TVAX Biomedical Inc, H2 2017 34
Anaplastic Astrocytoma - Pipeline by ZIOPHARM Oncology Inc, H2 2017 35
Anaplastic Astrocytoma - Dormant Projects, H2 2017 145
Anaplastic Astrocytoma - Discontinued Products, H2 2017 146